{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:13:24Z","timestamp":1789017204033,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["19K08807"],"award-info":[{"award-number":["19K08807"]}]},{"name":"Multiple Myeloma Research Grant from Myeloma Patients and Families, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00262-023-03447-x","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T17:02:05Z","timestamp":1681750925000},"page":"2635-2648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms"],"prefix":"10.1007","volume":"72","author":[{"given":"Asuka","family":"Shibamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Miyamoto-Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Rizq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaeko","family":"Nakajima-Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kayamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Oshima-Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokichi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koyama-Nasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-9428","authenticated-orcid":false,"given":"Naoya","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"3447_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger JA, Gribben JG (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Seminars Cancer Biol 24:71\u201381","journal-title":"Seminars Cancer Biol"},{"key":"3447_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1172\/JCI88169","volume":"128","author":"Y Kawano","year":"2018","unstructured":"Kawano Y, Zavidij O, Park J et al (2018) Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest 128:2487\u20132499. https:\/\/doi.org\/10.1172\/JCI88169","journal-title":"J Clin Invest"},{"key":"3447_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1172\/JCI77181","volume":"125","author":"C Guillerey","year":"2015","unstructured":"Guillerey C, Ferrari de Andrade L, Vuckovic S et al (2015) Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest 125:2077\u20132089. https:\/\/doi.org\/10.1172\/JCI77181","journal-title":"J Clin Invest"},{"key":"3447_CR4","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Prim 3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Prim"},{"key":"3447_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.exphem.2015.04.010","volume":"43","author":"N Mimura","year":"2015","unstructured":"Mimura N, Hideshima T, Anderson KC (2015) Novel therapeutic strategies for multiple myeloma. Exp Hematol 43:732\u2013741","journal-title":"Exp Hematol"},{"issue":"634\u201348","key":"3447_CR6","volume":"33","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Kassem S, Cleynen A et al (2018) Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell 33(634\u201348):e5","journal-title":"Cancer Cell"},{"key":"3447_CR7","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","volume":"67","author":"YM El-Sherbiny","year":"2007","unstructured":"El-Sherbiny YM, Meade JL, Holmes TD et al (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444\u20138449. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4230","journal-title":"Cancer Res"},{"issue":"2","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","volume":"63","author":"NE Kay","year":"1984","unstructured":"Kay NE, Zarling JM (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63(2): 305\u2013309. https:\/\/doi.org\/10.1182\/blood.V63.2.305.305","journal-title":"Blood"},{"key":"3447_CR9","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","volume":"66","author":"Z-Z Yang","year":"2006","unstructured":"Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM (2006) Attenuation of CD8+ T-cell function by CD4+ CD25+ regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma. Can Res 66:10145\u201310152","journal-title":"Can Res"},{"key":"3447_CR10","first-page":"1081","volume":"128","author":"I Azzaoui","year":"2016","unstructured":"Azzaoui I, Uhel F, Rossille D et al (2016) T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells Blood. J Am Soc Hematol 128:1081\u20131092","journal-title":"J Am Soc Hematol"},{"key":"3447_CR11","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/bloodadvances.2020003080","volume":"5","author":"M Roussel","year":"2021","unstructured":"Roussel M, Le KS, Granier C et al (2021) Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv 5:1816\u20131829. https:\/\/doi.org\/10.1182\/bloodadvances.2020003080","journal-title":"Blood Adv"},{"key":"3447_CR12","first-page":"1689","volume":"132","author":"C Guillerey","year":"2018","unstructured":"Guillerey C, Harjunp\u00e4\u00e4 H, Carri\u00e9 N et al (2018) TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma Blood. J Am Soc Hematol 132:1689\u20131694","journal-title":"J Am Soc Hematol"},{"key":"3447_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.014","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS et al (2020) Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014","journal-title":"Immunity"},{"key":"3447_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R et al (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326\u2013336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6","journal-title":"Nat Immunol"},{"key":"3447_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S (2021) CD8(+) T cell exhaustion in cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.715234","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"3447_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2018-99-114053","volume":"132","author":"O Rizq","year":"2018","unstructured":"Rizq O, Mimura N, Oshima M et al (2018) Utx insufficiency cooperates with Braf V600E in the induction of myeloma in mice. Blood 132(Supplement 1):1005","journal-title":"Blood"},{"key":"3447_CR17","doi-asserted-by":"publisher","first-page":"11493","DOI":"10.1158\/0008-5472.CAN-05-2211","volume":"65","author":"K Mercer","year":"2005","unstructured":"Mercer K, Giblett S, Green S, Lloyd D, Dias SD, Plumb M, Marais R, Pritchard C (2005) Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Can Res 65:11493\u201311500","journal-title":"Can Res"},{"key":"3447_CR18","first-page":"908","volume":"137","author":"Y Sera","year":"2021","unstructured":"Sera Y, Nakata Y, Ueda T et al (2021) UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes. Blood J Am Soc Hematol 137:908\u2013922","journal-title":"Blood J Am Soc Hematol"},{"key":"3447_CR19","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1073\/pnas.0602353103","volume":"103","author":"S Casola","year":"2006","unstructured":"Casola S, Cattoretti G, Uyttersprot N et al (2006) Tracking germinal center B cells expressing germ-line immunoglobulin \u03b31 transcripts by conditional gene targeting. Proc Natl Acad Sci 103:7396\u20137401","journal-title":"Proc Natl Acad Sci"},{"key":"3447_CR20","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187\u20132194. https:\/\/doi.org\/10.1084\/jem.20100643","journal-title":"J Exp Med"},{"key":"3447_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O, Giles JR, McDonald S et al (2019) TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571:211\u2013218. https:\/\/doi.org\/10.1038\/s41586-019-1325-x","journal-title":"Nature"},{"key":"3447_CR22","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo H, Chen J, Gonz\u00e1lez-Avalos E et al (2019) TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci 116:12410\u201312415","journal-title":"Proc Natl Acad Sci"},{"key":"3447_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, Lopez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A (2019) NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567:530\u2013534. https:\/\/doi.org\/10.1038\/s41586-019-0985-x","journal-title":"Nature"},{"key":"3447_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197357","volume-title":"Cellular and Molecular Mechanisms of CD8(+) T Cell Differentiation","author":"DJ Verdon","year":"2020","unstructured":"Verdon DJ, Mulazzani M, Jenkins MR (2020) Cellular and Molecular Mechanisms of CD8(+) T Cell Differentiation. Int J Mol Sci, Dysfunction and Exhaustion. https:\/\/doi.org\/10.3390\/ijms21197357"},{"key":"3447_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622509","author":"W Jiang","year":"2020","unstructured":"Jiang W, He Y, He W et al (2020) Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.622509","journal-title":"Front Immunol"},{"key":"3447_CR26","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G Gorgun","year":"2015","unstructured":"Gorgun G, Samur MK, Cowens KB et al (2015) Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 21:4607\u20134618. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0200","journal-title":"Clin Cancer Res"},{"key":"3447_CR27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178947","volume":"103","author":"S Danhof","year":"2018","unstructured":"Danhof S, Schreder M, Knop S, Rasche L, Strifler S, L\u00f6ffler C, Gogishvili T, Einsele H, Hudecek M (2018) Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Haematologica 103:e126","journal-title":"Haematologica"},{"key":"3447_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH et al (2020) Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1:493\u2013506. https:\/\/doi.org\/10.1038\/s43018-020-0053-3","journal-title":"Nat Cancer"},{"key":"3447_CR29","doi-asserted-by":"publisher","first-page":"20846","DOI":"10.1038\/s41598-020-77941-y","volume":"10","author":"EV Batorov","year":"2020","unstructured":"Batorov EV, Aristova TA, Sergeevicheva VV et al (2020) Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. Sci Rep 10:20846. https:\/\/doi.org\/10.1038\/s41598-020-77941-y","journal-title":"Sci Rep"},{"key":"3447_CR30","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/s41467-018-06653-9","volume":"9","author":"CA Egelston","year":"2018","unstructured":"Egelston CA, Avalos C, Tu TY et al (2018) Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression. Nat Commun 9:4297. https:\/\/doi.org\/10.1038\/s41467-018-06653-9","journal-title":"Nat Commun"},{"key":"3447_CR31","doi-asserted-by":"publisher","first-page":"20476","DOI":"10.18632\/oncotarget.24944","volume":"9","author":"K Fostier","year":"2018","unstructured":"Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, Schots R, De Keersmaecker B (2018) Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget 9:20476","journal-title":"Oncotarget"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03447-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:21:43Z","timestamp":1689996103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03447-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03447-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"20 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E. Sakaida received honoraria from Bristol Myers Squibb. No other potential conflict of interest relevant to this article was reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}